Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus VERARING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus VERARING.
DILACOR XR vs VERARING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Not available
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker